ctDNA Detection Panel
Immunotherapy is one of the newest treatment options available for cancer patients, and highly anticipated because of the initial positive results seen in many patients. However, these promising results are actually only seen in around 30% of the patients that undergo immunotherapy. We hope to identify the biomarkers present in the successful 30% of cancer patients in order to aid doctors on deciding whether immunotherapy is a recommended treatment or not for their patients.
QuarkBio is working towards developing a breast cancer prognosis classifier based on gene expression. By identifying related biomarkers, QuarkBio hopes to predict risk of breast cancer recurrence to aid clinicians in deciding on treatment strategies.
Lung cancer patients with the same genetic mutation do not always respond to the same treatment similarly, and may also develop tretment resistance towards drugs differently. QuarkBio aims to utilize gene expression biomarkers to monitor the effectiveness of lung cancer treatments and development of drug resistance, resulting in real-time oncology tracking.
Circulating tumor DNA is gaining traction as a potential clinical indication of tumor progression in the bloodstream - through liquid biopsy samples, QuarkBio is co-developing an assay that hopes to detect ctDNA in a cancer patient's bloodstream to see the progression of the cancer, recurrence, and/or treatment response.
QuarkBio is looking at fusion gene biomarkers that are potentially linked to leukemia patients and can help identify and classify leukemia patients in the future. The correct classification may assist doctors in deciding on the optimal method of treatment for these patients.
The initial symptoms for respiratory infections are alike regardless of the type of pathogens involved. It is critical to determine the cause in the early stage of the infection in order to prescribe appropriate medication.
The average age for getting married has been steadily increasing, leading to a growing number of couples that need to undergo in vitro fertilization (IVF) treatment in order to start a family. In vitro fertilization treatment’s success rate changes drastically depending on the woman’s age - from over 40% in her late 20s, to 30% at about age 38, and to 10% by about age 43. At QuarkBio, we’re working to identify biomarkers that can assist us in predicting when the ideal timing for implantation is based on the uterine environment in hopes of raising the success rate of IVF treatment.
Utilizing PanelChip® technology, QuarkBio collaborates with our partners to provide custom solutions for clinical diagnostic needs through three primary methods:
Drug and Biomarker
Identify cancer-related miRNA/RNA biomarkers from liquid biopsy samples through PanelChip® Analysis System.
Integrate and transfer your multiple molecular assays onto our PanelChip® Analysis System.
Position novel combinations of biomarkers onto PanelChip® Analysis System for your own customized, multi-gene assay.